浙江医学2018，Vol.40Issue(4)：365-367,3.DOI:10.12056/j.issn.1006-2785.2017.40.4.2017-243
莫西沙星替代异烟肼的4MRZE超短程化疗方案治疗初始肺结核的临床疗效
Short-course chemotherapy for pulmonary tuberculosis: 4MRZE versus 2HRZE/4HR
摘要
Abstract
Objective To compare the efficacy of short-course chemotherapy regime containing moxifloxacin (4MRZE) with conventional regime containing isoniazid (2HRZE/4HR) for pulmonary tuberculosis.Methods Eighty pulmonary tuberculosis patients with positive sputum smear and culture admitted in Hangzhou Tuberculosis Control Institute from November 2013 to January 2016,were enrolled in the study.Patients were randomly assigned in two groups:40 patients received moxifloxacin,rifampicin,pyrazinamide and ethambutol for 4 months (4MRZE,study group),and 40 patients received isoniazid,rifampicin,pyrazinamide and ethambutol for 6 months (2HRZE/4HR,control group).All the patients were followed up for sputum examination,X rays and adverse reactions.Results The compliance in both groups was good,and no patient dropped out.The sputum examination and the X rays results were significant improved after treatment in both groups,there were no significant differences at month 1,2,3,4 and the end of the treatment between two groups (P ＞0.05).However,the overall incidence of the adverse reactions were significantly lower in the study group than that in the control group (P＜0.05);however,there were no significant differences in the incidence of individual adverse reactions between two groups (P ＞0.05).Conclusion The efficacy of chemotherapy regime with moxifloxacin and that with isoniazid is similar for treatment of pulmonary tuberculosis,but the overall adverse reactions are significantly lower in the regime with moxifloxacin included.关键词
莫西沙星/异烟肼/初始肺结核Key words
Moxifloxacin/Isoniazid/Pulmonary tuberculosis引用本文复制引用
蔡青山,朱敏,陈园园,夏强,孙亚萍..莫西沙星替代异烟肼的4MRZE超短程化疗方案治疗初始肺结核的临床疗效[J].浙江医学,2018,40(4):365-367,3.基金项目
浙江省医药卫生科技计划项目(2015PYA008) （2015PYA008）
